2020年新型冠状病毒分子病理学研究及其药物和疫苗研发热点回眸

叶盛

doi:10.3981/j.issn.1000-7857.2021.01.012

PDF(6296 KB)

科技导报 ›› 2021, Vol. 39 ›› Issue (1) : 144-165. DOI: 10.3981/j.issn.1000-7857.2021.01.012

专题：2020年科技热点回眸

2020年新型冠状病毒分子病理学研究及其药物和疫苗研发热点回眸

叶盛

作者信息 -

北京航空航天大学医工交叉创新研究院; 北航-首医大数据精准医疗高精尖创新中心, 北京 100191

作者简介:

叶盛,研究员,研究方向为病毒性传染病和癌症等重大疾病的分子病理机制,电子信箱:yesheng@buaa.edu.cn

A review of SARS-CoV-2 in 2020: Molecular pathology and drugs and vaccines in development

YE Sheng

Author information -

Interdisciplinary Innovation Institute of Medicine & Engineering, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China

摘要

新型冠状病毒于2019年12月被发现以来，引发了严重的呼吸系统传染病疫情，并波及世界所有主要国家和地区。全球科学界迅速行动起来，对该病毒及其引发的疾病进行了广泛而深入的研究。得益于此前在严重急性呼吸道综合征冠状病毒和中东呼吸综合征冠状病毒上的知识积累，针对新型冠状病毒的科研工作在2020年取得了丰硕的研究成果，特别是在分子病理学方面获得了很多透彻的认知，这些知识的获得又为针对新型冠状病毒的药物和疫苗研发奠定了基础。简要回顾了冠状病毒的研究历史，重点总结了新型冠状病毒的分子病理学研究要点，在药物研发方面兼顾现有药物的重定位和新型抗病毒药物的研发现状，在疫苗研发方面按类型总结各国目前比较成功的疫苗项目及其研发进展。

Abstract

Since SARS-CoV-2 was discovered in December 2019, the coronavirus has caused a serious pandernic of severe respiratory infectious disease, which subsequently spread globally. The scientific community reacted immediately to perform comprehensive and exhaustive studies on SARS-CoV-2 and the diseases it caused. Benefited from the knowledge accumulated in previous studies of SARS-CoV and MERS-CoV, the research work of SARS-CoV-2 got extensive achievements in 2020, especially in molecular pathology. Mastering the knowledge has built a solid foundation for the drug and vaccine development against SARS-CoV-2. In this review, the research history of coronaviruses is briefly reviewed, followed by a summary of molecular pathological studies on SARS-CoV-2 in 2020, as well as the progress of drug and vaccine development against SARS-CoV-2.

导出引用

叶盛. 2020年新型冠状病毒分子病理学研究及其药物和疫苗研发热点回眸[J]. 科技导报, 2021, 39(1): 144-165 https://doi.org/10.3981/j.issn.1000-7857.2021.01.012

YE Sheng. A review of SARS-CoV-2 in 2020: Molecular pathology and drugs and vaccines in development[J]. Science & Technology Review, 2021, 39(1): 144-165 https://doi.org/10.3981/j.issn.1000-7857.2021.01.012

参考文献

[1] Zhu N, Zhang D, China Novel Coronavirus Investigating and Research Team, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. New England Journal of Medicine, 2020, 382(8):727-733.
[2] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, Gorbalenya A E, Baker S C, et al. The species severe acute respiratory syndrome-related coronavirus:Classifying 2019-nCoV and naming it SARS-CoV-2[J]. Nature Microbiology, 2020, 5:536-544.
[3] World Health Organization. WHO coronavirus disease (COVID-19) dashboard[EB/OL]. (2019-03-11)[2020-12-21]. https://covid19.who.int/.
[4] Estola T. Coronaviruses, a new group of animal RNA viruses[J]. Avian Disease, 1970, 14(2):330-336.
[5] Beach J R, Schalm O W. A filtrable virus distinct from that of laryngotracheitis:the cause of a respiratory disease of chicks[J]. Poultry Science, 1936, 15:199-206.
[6] Lalchhandama K. The chronicles of coronaviruses:The bronchitis, the hepatitis and the common cold[J]. Science Vision, 2020, 20(1):43-53.
[7] Kendall E J, Bynoe M L, Tyrrell D A. Virus isolations from common colds occurring in a residential school[J]. British Medical Journal, 1962, 2(5297):82-86.
[8] Hamre D, Procknow J J. A new virus isolated from the human respiratory tract[J]. Proceedings of the Society for Experimental Biology and Medicine, 1966, 121(1):190-193.
[9] Berry D M, Cruickshank J G, Chu H P, et al. The structure of infectious bronchitis virus[J]. Virology, 1964, 23:403-407.
[10] Almeida J D, Tyrrell D A. The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture[J]. Journal of General Virology, 1967, 1(2):175-178.
[11] McIntosh K, Dees J H, Becker W B, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease[J]. Proceedings of the National Academy of Sciences of the United States of America, 1967, 57(4):933-940.
[12] Almeida J D, Berry D M, Cunningham C H, et al. Virology:Coronaviruses[J]. Nature, 1968, 220(5168):650.
[13] Cavanagh D. Severe acute respiratory syndrome vaccine development:Experiences of vaccination against avian infectious bronchitis coronavirus[J]. Avian Pathology, 2003, 32:567-582.
[14] Chan-Yeung M, Xu R H. SARS:Epidemiology[J]. Respirology, 2003, 8(S1):9-14.
[15] van der Hoek L, Pyrc K, Jebbink M F, et al. Identification of a new human coronavirus[J]. Nature Medicine, 2004, 10(4):368-373.
[16] Woo P C, Lau S K, Chu C M, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia[J]. Journal of Virology, 2005, 79(2):884-895.
[17] World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)[EB/OL]. (2019-03-11)[2020-12-21]. https://www.who.int/health-topics/middleeast-respiratory-syndrome-coronavirus-mers.
[18] Neiderud C J. How urbanization affects the epidemiology of emerging infectious diseases[J]. Infection Ecology & Epidemiology, 2015, 5:27060.
[19] Jones K, Patel N, Levy M et al. Global trends in emerging infectious diseases[J]. Nature, 2008, 451:990-993.
[20] Hu B, Zeng L P, Yang X L, et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus[J]. PLoS Pathogens, 2017, 13(11):e1006698.
[21] Müller M A, Corman V M, Jores J, et al. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997[J]. Emerging Infectious Diseases, 2014, 20(12):2093-2095.
[22] King A M Q, Adams M J, Carstens E B, et al. Virus taxonomy:classification and nomenclature of viruses:ninth report of the International Committee on Taxonomy of Viruses[R]. London:the International Committee on Taxonomy of Viruses, 2011.
[23] Brian D A, Baric R S. Coronavirus genome structure and replication[J]. Current Topics in Microbiology and Immunology, 2005, 287:1-30.
[24] Ziebuhr J. Molecular biology of severe acute respiratory syndrome coronavirus[J]. Current Opinion in Microbiology, 2004, 7(4):412-419.
[25] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. The Lancet, 2020, 395(10223):497-506.
[26] Zhou P, Yang X L, Wang X G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798):270-273.
[27] Li W, Moore M, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature, 2003, 426:450-454.
[28] Mossel E C, Wang J, Jeffers S, et al. SARS-CoV replicates in primary human alveolar type Ⅱ cell cultures but not in type I-like cells[J]. Virology, 2008, 372(1):127-135.
[29] Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor[J]. Nature, 2020, 581:215-220.
[30] Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2[J]. Nature, 2020, 581:221-224.
[31] Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2[J]. Science, 2020, 367:1444-1448.
[32] Li F, Li W, Farzan M, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor[J]. Science, 2005, 309:1864-1868.
[33] Wang K, Chen W, Zhang Z, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells[J]. Signal Transduction and Targeted Therapy, 2020, 5:283.
[34] Chen Y, Liu Q, Guo D. Emerging coronaviruses:Genome structure, replication, and pathogenesis[J]. Journal of Medical Virology, 2020, 92(4):418-423.
[35] Wrapp D, Wang N, Corbett K S, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367(6483):1260-1263.
[36] Pallesen J, Wang N, Corbett K S, et al. Immunogenicity and structures of a rationally designed prefusion MERSCoV spike antigen[J]. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114(35):7348-7357.
[37] Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein[J]. Science, 2020, 369(6511):1586-1592.
[38] Walls A C, Park Y J, Tortorici M A, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020, 181(2):281-292.
[39] Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein:Targets for vaccination[J]. Life Science, 2020, 257:118056.
[40] Fan X, Cao D, Kong L, et al. Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein[J]. Nature Communications,2020, 11(1):3618.
[41] Walls A C, Xiong X, Park Y J, et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion[J]. Cell, 2019, 176:1026-1039.
[42] Yao H, Song Y, Chen Y, et al. Molecular architecture of the SARS-CoV-2 virus[J]. Cell, 2020, 183(3):730-738.
[43] Ke Z, Oton J, Qu K, et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions[J]. Nature, 2020, 588:498-502.
[44] Liu C, Mendonça L, Yang Y, et al. The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by Cryo-EM and Cryo-ET[J]. Structure, 2020, 28(11):1218-1224.
[45] Yang H, Yang M, Ding Y, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor[J]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(23):13190-13195.
[46] Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARSCoV-2 and discovery of its inhibitors[J]. Nature, 2020, 582:289-293.
[47] Gao Y, Yan L, Huang Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus[J]. Science, 2020, 368(6492):779-782.
[48] Yan L, Zhang Y, Ge J. et al. Architecture of a SARSCoV-2 mini replication and transcription complex[J]. Nature Communications, 2020, 11:5874.
[49] Wang Q, Wu J, Wang H, et al. Structural basis for RNA replication by the SARS-CoV-2 polymerase[J]. Cell, 2020, 182(2):417-428.
[50] The Pharmaceutical Research and Manufacturers of America. Biopharmaceutical R&D:The process behind new medicines[R]. Washington DC:PhRMA, 2015.
[51] Beigel J H, Tomashek K M, Dodd L E. Remdesivir for the treatment of Covid-19-Final report[J]. New England Journal of Medicine, 2020, 383:1813-1826.
[52] WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19-Interim WHO solidarity trial results[J]. New England Journal of Medicine, 2020, doi:10.1056/NEJMoa2023184.
[53] Omrani A S, Saad M M, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection:a retrospective cohort study[J]. The Lancet Infectious Diseases, 2014, 14:1090-1095.
[54] Khalili J S, Zhu H, Mak N S A, et al. Novel coronavirus treatment with ribavirin:Groundwork for an evaluation concerning COVID-19[J]. Journal of Medical Virology, 2020, 92(7):740-746.
[55] Tong S, Su Y, Yu Y, et al. Ribavirin therapy for severe COVID-19:A retrospective cohort study[J]. International Journal of Antimicrobial Agents, 2020, 56(3):106114.
[56] Kaptein S J F, Jacobs S, Langendries L, et al. Favipiravir at high doses has potent antiviral activity in SARSCoV-2-infected hamsters, whereas hydroxychloroquine lacks activity[J]. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117(43):26955-26965.
[57] Shrestha D B, Budhathoki P, Khadka S, et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment:A rapid systematic review and meta-analysis[J]. Virology Journal, 2020, 17:141.
[58] Muralidharan N, Sakthivel R, Velmurugan D, et al. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARSCoV-2 protease against COVID-19[J]. Journal of Biomolecular Structure & Dynamics, 2020, 16:1-6.
[59] Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19[J]. New England Journal of Medicine, 2020, 382(19):1787-1799.
[60] Jin Z, Zhao Y, Sun Y, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur[J]. Nature Structural & Molecular Biology, 2020, 27:529-532.
[61] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Research, 2020, 30(3):269-271.
[62] Sun J, Chen Y, Fan X, et al. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19[J]. Postgraduate Medicine, 2020, 132(7):604-613.
[63] Pillaiyar T, Manickam M, Namasivayam V, et al. An overview of severe acute respiratory syndrome-coronavirus(SARS-CoV) 3CL protease inhibitors:peptidomimetics and small molecule chemotherapy[J]. Journal of Medicine Chemistry, 2016, 59(14):6595-6628.
[64] Liang R, Wang L, Zhang N, et al. Development of smallmolecule MERS-CoV inhibitors[J]. Viruses, 2018, 10(12):721.
[65] Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target[J]. Bioorganic & Medicinal Chemistry Letters, 2020, 30(17):127377.
[66] Zhang L, Lin D, Sun X, et al. Crystal structure of SARSCoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors[J]. Science, 2020, 368(6489):409-412.
[67] Yang H, Xie W, Xue X, et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases[J]. PLoS Biology, 2005, 3(10):e324.
[68] Dai W, Zhang B, Su H, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease[J]. Science, 2020, 368(6497):1331-1335.
[69] Walls A C, Xiong X, Park Y J, et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion[J]. Cell, 2019, 176(5):1026-1039.
[70] Berry J D, Hay K, Rini J M, et al. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology[J]. mAbs, 2010, 2(1):53-66.
[71] Ter Meulen J, van den Brink E N, Poon L L M, et al. Human monoclonal antibody combination against SARS coronavirus:synergy and coverage of escape mutants[J]. PLoS Medicine, 2006, 3(7):e237.
[72] Prabakaran P, Gan J, Feng Y, et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody[J]. Journal of Biological Chemistry, 2006, 281(23):15829-15836.
[73] Zhu Z, Chakraborti S, He Y, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(29):12123-12128.
[74] Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection[J]. Nature Communications, 2020, 11:2251.
[75] Barnes C O, Jette C A, Abernathy M E, et al. SARSCoV-2 neutralizing antibody structures inform therapeutic strategies[J]. Nature, 2020, 588:682-687
[76] Huo J, Le Bas A, Ruza R R, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2[J]. Nature Structural & Molecular Biology, 2020, 27:846-854.
[77] Monteil V, Kwon H, Prado P, et al. Inhibition of SARSCoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2[J]. Cell, 2020, 181:905-913.
[78] Chan K K, Dorosky D, Sharma P, et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2[J]. Science, 2020, 369:1261-1265.
[79] Cao L, Goreshnik I, Coventry B, et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors[J]. Science, 2020, 370(6515):426-431.
[80] Shi X J, Li Y, Yan L, et al. Neutralizing antibodies targeting SARS-CoV-2 spike protein[J]. Stem Cell Research, 2020, 50:102125.
[81] Zhu Y, Yu D, Yan H, et al. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity[J]. Journal of Virology, 2020, 94(14):e00635-20.
[82] Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor[J]. Nature Communications, 2014, 5:3067.
[83] Xia S, Yan L, Xu W, et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike[J]. Science Advances, 2019, 5(4):eaav4580.
[84] Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2(previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion[J]. Cell Research, 2020, 30(4):343-355.
[85] Krammer, F. SARS-CoV-2 vaccines in development[J]. Nature, 2020, 586:516-527.
[86] World Health Organization. DRAFT landscape of COVID-19 candidate vaccines[R]. Geneva:WHO, 2020.
[87] Tseng C T, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus[J]. PLoS ONE, 2012, 7:e35421.
[88] Houser K V, Broadbent A J, Gretebeck L, et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody[J]. PLoS Pathogens, 2017, 13(8):e1006565.
[89] Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2[J]. Science, 2020, 369(6499):77-81.
[90] Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes:Interim analysis of 2 randomized clinical trials[J]. The Journal of the American Medical Association, 2020, 324(10):951-960.
[91] Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2[J]. Cell, 2020, 182(3):713-721.
[92] Palacios R, Patiño E G, de Oliveira Piorelli R, et al. Double-blind, randomized, placebo-controlled phase Ⅲ clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19(Inactivated) vaccine manufactured by sinovac-PROFISCOV:A structured summary of a study protocol for a randomised controlled trial[J]. Trials, 2020, 21(1):853.
[93] Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans[J]. Nature Medicine, 2020, 26(7):1033-1036.
[94] Liu L, Wang P, Nair M S, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike[J]. Nature, 2020, 584(7821):450-456.
[95] Kirchdoerfer R N, Wang N, Pallesen J, et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis[J]. Scientific Reports, 2018, 8(1):15701.
[96] Hsieh C L, Goldsmith J A, Schaub J M, et al. Structurebased design of prefusion-stabilized SARS-CoV-2 spikes[J]. Science, 2020, 369(6510):1501-1505.
[97] Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine[J]. New England Journal of Medicine, 2020, 383(24):2320-2332.
[98] Moderna Inc. Moderna announces primary efficacy analysis in phase 3 COVE study for its COVID-19 vaccine candidate and filing today with U.S. FDA for emergency use authorization[EB/OL]. (2020-11-30)[2020-12-21]. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacyanalysis-phase-3-cove-study.
[99] Pfizer Inc. Pfizer and biontech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints[EB/OL]. (2020-11-18)[2020-12-21]. https://www.pfizer.com/news/press-release/press-releasedetail/pfizer-and-biontech-conclude-phase-3-studyCOVID-19-vaccine.
[100] Marzi A, Robertson S J, Haddock E, et al. Ebola Vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain[J]. Science, 2015, 349(6249):739-42.
[101] Zhu F C, Guan X H, Li Y H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older:a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2020, 396(10249):479-488.